Polaris Capital Group

Polaris focuses on three dislocation-driven origination channels: management buyouts triggered by founder succession, carve-outs and spin-offs of non-core businesses from large Japanese corporations, and take-private transactions of listed companies. The firm’s Osaka branch provides a differentiated pipeline into Kansai-region, owner-operated enterprises that are often underrepresented in competitive auction processes run out of Tokyo. A Singapore subsidiary also supports post-acquisition cross-border expansion for portfolio companies.

Polaris employs a control-oriented buyout model spanning traditional leveraged buyouts, management buyouts, secondary buyouts, and public-to-private transactions. In healthcare and technology, the firm has articulated a deliberate growth-buyout strategy that layers capital for commercial expansion onto the standard leveraged-buyout structure, as seen in its investments in AI-software provider Stockmark and orthopaedic-device company Osferion Biomaterial.

The firm concentrates on four sectors: globally competitive manufacturing and technology, healthcare and welfare services with an ESG angle, IT and logistics, and consumer goods and retail brands with global potential. There is no publicly stated exclusion list, but Polaris does not advertise exposure to financial services, energy extraction, or infrastructure, and its portfolio contains no pure-play fintech, biotech drug development, or heavy-industry commodity businesses.

Through April 2026, Polaris completed six fund vintages and had raised ¥550 billion in aggregate commitments (per the firm, 2026). The firm reports 48 investments since inception, spanning carve-outs, founder-succession transitions, privatizations, and secondary buybacks, with realized exits including Space Value Holdings (prefabricated building systems), Linkstech (printed wiring boards), and Sogo Medical Group (pharmacy and medical support).